Developmental Research Program

发展研究计划

• 批准号: 7314960
• 负责人: PETER NELSON
• 金额: $ 18.29万
• 依托单位: FRED HUTCHINSON CANCER RESEARCH CENTER
• 依托单位国家: 美国
• 财政年份: 2007
• 资助国家: 美国
• 起止时间: 2007-07-01 至 2012-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7314960
• 关键词: Address; Area; Biological; British Columbia; Canada; Cancer Patient; Development; Diagnosis; Disease; Environment; Etiology; Fred Hutchinson Cancer Research Center; Funding; Funding Agency; General Hospitals; Genetic; Goals; Grant; Guidelines; Health Sciences; Institutes; Institution; Knowledge; Leadership; Malignant neoplasm of prostate; Morbidity - disease rate; Neoplasm Metastasis; Oregon; Pacific Northwest; Pilot Projects; Prevention; Prostate; Publications; Purpose; Quality of life; Reproduction spores; Research; Research Personnel; Research Project Grants; Systems Biology; Translational Research; United States National Institutes of Health; Universities; Washington; anticancer research; base; expectation; improved; innovation; mortality; programs; research study

The main purpose of the Developmental Research Program (DRP) of the Pacific Northwest (PNW) Prostate Cancer SPORE is to support innovative translational prostate cancer (PC) research pilot projects aimed at reducing the morbidity and mortality due to PC and at improving the survival and quality of life of PC patients. During the initial funding of the DRP, substantial progress has been made in the development and implementation of this unique and successful research program. During the first four years of the DRP, 46 pilot project proposals were submitted and 19 projects were funded (total of $798,100.00 direct funding). Ten publications and 7 grants have resulted to date from the DRP. For this continuation grant, the DRP program will continue to provide a mechanism to quickly respond to new translational research opportunities that may develop within the SPORE environments of participating institutions: Vancouver General Hospital (VGH) Prostate Centre in Vancouver, British Columbia, Canada; the University of Washington (UW), the Fred Hutchinson Cancer Research Center (FHCRC), and the Institute for Systems Biology (ISB) in Seattle, WA; and, Oregon Health Sciences University (OHSU) in Portland, OR. Support provided by the DRP will continue to allow innovative pilot projects to be initiated, with the expectation that the projects will mature sufficiently so that they can successfully compete for additional funding from sources either within or outside the SPORE grant. This program also attracts more senior investigators with diverse scientific expertise and new investigators into translational PC research. The specific aims for the DRP are: 1) Solicit innovative, translational prostate cancer research study proposals for pilot funding on an annual basis; 2) Convene a panel of experts to provide rigorous scientific review of pilot study proposals following NIH guidelines for selection of the most promising research projects; 3) Provide pilot study funding for 1-2 years for the most innovative investigator-initiated ideas for research in all areas of prostate cancer research (including etiology, prevention, diagnosis, biological mechanisms, genetics, and treatment) with a special emphasis on projects that address issues relevant to advancing knowledge of disease aggressiveness or metastasis; and, 4) Allow the SPORE leadership to target funds to specific areas that are especially likely to advance the translational research goals of the PNW prostate cancer SPORE.

太平洋西北开发研究计划(DRP)的主要目的 前列腺癌孢子将支持创新的转化型前列腺癌(PC)研究试点项目 旨在降低PC的发病率和死亡率，提高PC患者的生存和生活质量 PC患者。在DRP的最初筹资期间，在发展方面取得了实质性进展 并实施这一独特而成功的研究计划。在DRP的头四年里， 提交了46个试点项目提案，资助了19个项目(直接供资总额为798,100美元)。 到目前为止，DRP已经出版了10份出版物和7份赠款。对于这笔续期拨款，DRP 计划将继续提供一种机制，以快速响应新的翻译研究机会 可能在参与机构的孢子环境中发展：温哥华综合医院 (VGH)加拿大不列颠哥伦比亚省温哥华的前列腺中心；华盛顿大学(UW)， 弗雷德·哈钦森癌症研究中心(FHCRC)和西雅图系统生物学研究所(ISB)， 以及俄勒冈健康科学大学(OHSU)，位于俄勒冈州波特兰市。由DRP提供的支持将 继续允许启动创新的试点项目，期望项目成熟 足够让他们能够成功地从内部或外部来源竞争额外的资金 孢子金。该计划还吸引了更多具有不同科学专业知识和 对翻译PC研究的新调查人员。DRP的具体目标是： 1)征集创新的、可翻译的前列腺癌研究研究提案，用于试点资助，每年 依据； 2)召集一个专家小组，对NIH之后的试点研究提案进行严格的科学审查 选择最有希望的研究项目的指导方针； 3)为最具创新性的研究人员发起的想法提供1-2年的试点研究资金 前列腺癌研究的所有领域(包括病因、预防、诊断、生物学 机制、遗传学和治疗)，特别强调解决问题的项目 与增进有关疾病侵袭性或转移的知识有关；以及 4)允许孢子领导层将资金集中到特别有可能推动 PNW前列腺癌孢子的翻译研究目标。